Skip to main content

Table 3 Designed therapies

From: Androgenic suppression combined with radiotherapy for the treatment of prostate adenocarcinoma: a systematic review

Author Year Radiotherapy (dose) Hormone Therapy Duration N Median follow up
Zagars 1988 70 Gy Diethylstilbestrol 25 mg PO qd Continuously 82 14.5 years
Laverdiere 2004 64 Gy Leuprolide 7.5 mg/month +
Flutamide
3 months
or
10 months
161 5 years
Lawton 2005 65 to 70 Gy Goserelin 3.6 mg/month Continuously 977 6.5 years
Granfors 2006 60 to 70 Gy Orchiectomy Permanent 91 9.7 years
See 2006 NS Bicalutamide 150 mg PO qd Decided by investigator 1370 7.2 years
D'Amico 2008 NS Goserelin 3,6 mg or
Leuprolide 7.5 mg/month +
Flutamide
6 months 206 8.2 years
Roach 2008 65 to 70 Gy Goserelin 3.6 mg/month + Flutamide 3 months 456 11.9 years
Bolla 2010 70 Gy Goserelin 3.6 mg/month 3 years 415 9.1 years
Denham 2011 66 Gy Goserelin 3.6 mg/month +
Flutamide
3 months
or
6 months
818 10.6 years
Jones 2011 66.6 Gy Goserelin 3,6 mg or
Leuprolide 7.5 mg/month +
Flutamide
4 months 1979 9.1 years
  1. Abbreviations: Gy Gray unit, N number of patients, NS not stated, PO oral administration, qd every day